Autopsy report · NCT01931566

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

“Lack of efficacy of the drug; no safety concern”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 5 years 1 month before it stopped.
• 3,494 participants enrolled.
• Results were posted on the registry 11 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Takeda

Sponsor type

Industry

Conditions

Mild Cognitive Impairment Due to Alzheimer's Disease

Interventions

Pioglitazone; Pioglitazone placebo

Participants

3,494

Sites

55

Countries

Australia, Germany, Switzerland, United Kingdom, United States

Trials that died the same way

• Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
  “Lack of Efficacy, no safety concern.” (79% match in meaning)
• Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage Dysplasia
  “Lack of efficacy” (76% match in meaning)
• Topical Garlic Concentrate for Alopecia Areata in Children
  “Lack of efficacy of the study medication” (76% match in meaning)
• Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
  “Not related to safety concerns or lack of efficacy” (75% match in meaning)
• Cross Linking for Treatment of Corneal Infection
  “insufficient efficacy” (75% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.